Pro Life Medica Sp. z o.o.

Lublin 43 trials 7 recruiting

43 Registered trials

7 Currently recruiting

Organisation

Pro Life Medica Sp. z o.o.

Location

Lublin, Poland

Identifier

ORG-100047173

Address

Ul. Wladyslawa Kunickiego 26a, 20-412, Poland

Departments

"ETG Lublin Prof. Life Medica Sp. z o. o."
2215:ETG Lublin
Chronic pain
Dermatology Department
ETG Dębica
ETG Lublin
ETG Poniatowa
ETG Zamość
n/a
NA
Neurology
Orthopedics
PL10004: gastroenterology
PL10017:ETG Zamość
PL10045_ETG Zamosc
Pro Life Medica Sp z o o ETG Zamosc
Pro Life Medica Sp. z o.o ETG Lublin

Clinical trials at this site (43)

Search interface

A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease Pending

2024-515448-22-00 Parkinson 4
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w… Recruiting

2023-507853-13-00 Ulcerative Colitis 4 2025-02-25
A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti… Recruiting

2024-513053-69-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting

2023-508234-34-00 Crohn's disease 4 2025-01-27
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis Recruiting

2023-508817-18-00 Perennial Allergic Rhinitis (PAR) 5 2024-10-08
A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting

2023-506704-14-00 Moderately to Severely Active Crohn's Disease 4 2024-09-04
Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting

2023-503327-26-00 Sjogren's syndrome 5 2024-01-31
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended

2024-516609-22-00 Primary Sjögren’s Disease 5 2025-04-15
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED) Ended

2024-514973-23-00 Thyroid eye disease 5 2025-02-25
Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended

2023-504040-34-01 Crohn’s Disease 5 2024-11-12
A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease. Ended

2022-502789-26-01 Fibrostenotic Crohn’s Disease 4 2023-11-03
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended

2024-515027-11-00 Crohn’s disease 4 2023-06-29
A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC Ended

2022-500953-17-00 Moderately to severely active ulcerative colitis 4 2023-03-23
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely… Ended

2023-504719-34-00 Moderate to Severly Active Ulcerative Colitis 5 2023-02-21
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t… Ended

2023-504737-41-00 Moderately to Severely Active Crohn's Disease 5 2022-06-10
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended

2023-504716-15-00 Psoriatic Arthritis 6 2021-08-06